Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost
Vaishali Shukla, Enrique Seoane‐Vazquez, Souhiela Fawaz, et al.
Human Gene Therapy Clinical Development (2019) Vol. 30, Iss. 3, pp. 102-113
Closed Access | Times Cited: 71

Showing 26-50 of 71 citing articles:

Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products
Peter Childs, S. Reid, Manuel Salmerón‐Sánchez, et al.
Biochemical Journal (2020) Vol. 477, Iss. 17, pp. 3349-3366
Open Access | Times Cited: 21
mRNA: vaccine or gene therapy? The safety regulatory issues
Hélène Banoun
(2023)
Open Access | Times Cited: 7
Estimation of manufacturing development costs of cell-based therapies: a feasibility study
Renske M.T. ten Ham, Julianne C. Nievaart, Jarno Hoekman, et al.
Cytotherapy (2021) Vol. 23, Iss. 8, pp. 730-739
Open Access | Times Cited: 18
Oncolytic virus preclinical toxicology studies
Agnija Rasa, Pēteris Alberts
Journal of Applied Toxicology (2022) Vol. 43, Iss. 5, pp. 620-648
Closed Access | Times Cited: 12
Study on Preclinical Safety and Toxic Mechanism of Human Umbilical Cord Mesenchymal Stem Cells in F344RG Rats
Xiaofang Hao, Hao Zhu, Chao Qin, et al.
Stem Cell Reviews and Reports (2024)
Open Access | Times Cited: 2
Genome-based therapeutic interventions for β-type hemoglobinopathies
Kariofyllis Karamperis, Maria T. Tsoumpeli, Fotios Kounelis, et al.
Human Genomics (2021) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Impact of Bioreactor Geometry on Mesenchymal Stem Cell Production in Stirred‐Tank Bioreactors
Florian Petry, Denise Salzig
Chemie Ingenieur Technik (2021) Vol. 93, Iss. 10, pp. 1537-1554
Open Access | Times Cited: 14
Novel Ellipsoid Chitosan-Phthalate Lecithin Nanoparticles for siRNA Delivery
Ramzi Mukred Saeed, Mohammad S. Abdullah, Mamoun Ahram, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 13
Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review
Lorena Aguilera-Cobos, María Piedad Rosario-Lozano, Angela Ponce-Polo, et al.
Health Policy (2022) Vol. 126, Iss. 12, pp. 1248-1255
Open Access | Times Cited: 8
Introduction of managed entry agreements in Korea: Problem, policy, and politics
Hyungmin Kim, Brian Godman, Hye-Young Kwon, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
The Dog Model in the Spotlight: Legacy of a Trustful Cooperation
Inès Barthélémy, Christophe Hitte, Laurent Tiret
Journal of Neuromuscular Diseases (2019) Vol. 6, Iss. 4, pp. 421-451
Open Access | Times Cited: 12
Absorption of liquid nitrogen into porous materials used in the cryogenic cold chain
R.M.A. Spijkers, Srinivas Vanapalli
Cryogenics (2024) Vol. 143, pp. 103936-103936
Open Access | Times Cited: 1
Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience
Paloma Gastelurrutia, Cristina Prat‐Vidal, Joaquim Vives, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 9
Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
Maria Kamusheva, Adina Turcu-Știolică, Jakub Gierczyński, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 9
The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
Genevieve Shemie, Minh Thu Nguyen, J. Wallenburg, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 5, pp. 382-382
Open Access | Times Cited: 8
The impact of The Rare Disease and Orphan Drug Act in Taiwan
Ning-Chun Hsiang, Weng‐Foung Huang, Churn‐Shiouh Gau, et al.
Journal of Food and Drug Analysis (2021) Vol. 29, Iss. 4, pp. 717-725
Open Access | Times Cited: 8
Design of experiments as a decision tool for cell therapy manufacturing
Esmond Lee, Devin Shah, Matthew H. Porteus, et al.
Cytotherapy (2022) Vol. 24, Iss. 6, pp. 590-596
Closed Access | Times Cited: 6
Illustrative Potency Assay Examples from Approved Therapies
Sílvia Torrents, Marta Grau-Vorster, Joaquim Vives
Advances in experimental medicine and biology (2023), pp. 139-149
Closed Access | Times Cited: 3
Comparison of cell viability methods for human mesenchymal/stromal stem cells and human A549 lung carcinoma cells after freeze-thaw stress
Markus Kardorff, Hanns‐Christian Mahler, Jörg Huwyler, et al.
Journal of Pharmacological and Toxicological Methods (2023) Vol. 124, pp. 107474-107474
Closed Access | Times Cited: 3
Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
Ryosuke Kurauchi, Hiroi Kasai, Tatsuya Ito
Frontiers in Bioengineering and Biotechnology (2020) Vol. 8
Open Access | Times Cited: 8
Orphan drug development: The impact of regulatory and reimbursement frameworks
Yujun Huang, Wan-Yu Chao, Chi‐Chuan Wang, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1724-1732
Closed Access | Times Cited: 5
Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies
Carsten W. Lederer, Lola Koniali, Tina Buerki‐Thurnherr, et al.
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 793-793
Open Access | Times Cited: 5
Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products
Joaquim Vives, Luciano Rodrı́guez, María Isabel Coca, et al.
Methods in molecular biology (2020), pp. 251-261
Closed Access | Times Cited: 7
Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
Dong‐Sook Kim, Geunwoo Lee, Hyungyung Cho, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 7
Perspectives, Expectations, and Concerns of European Patient Advocates on Advanced Therapy Medicinal Products
Stefano Benvenuti, Chiuhui Mary Wang, Simona Borroni
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 6

Scroll to top